OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Garmezy on Considerations For Frontline Treatment Selection in ccRCC

January 19th 2024

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Dr Shah on the 5-Year Survival Outcomes From the KEYNOTE-590 Study in Esophageal Cancer

January 19th 2024

Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer

January 19th 2024

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRC

January 18th 2024

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Dr Bazhenova on the Need for Comprehensive Molecular Testing in Unresectable NSCLC

January 18th 2024

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

Dr Choi on Potential Treatment Options in R/R CLL Following Progression on a Covalent BTK Inhibitor

January 17th 2024

Michael Choi, MD, discusses subsequent treatments for patients with relapsed/refractory CLL who progressed on a prior covalent BTK inhibitor.

Dr Jones on Communication Between Community and Academic Oncologists in Cancer Care

January 17th 2024

Robin Jones, MD, MRCP, discusses the importance of communication between community and academic oncologists in cancer care.

Dr Kim on Ongoing and Planned Research in HCC at Moffitt Cancer Center

January 17th 2024

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

Dr Phillips on Ongoing Research to Address Unmet Needs in Patients With High-Risk MCL

January 17th 2024

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Dr Powles on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer

January 16th 2024

Thomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.

Dr Gruenwald on Tumor Responses With Lenvatinib Plus Pembrolizumab in Advanced RCC

January 16th 2024

Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.

Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

January 16th 2024

Adam M. Brufsky, MD, PhD, FACP, discusses the remaining questions following the FDA approval of capivasertib/fulvestrant in HR+/HER2- breast cancer.

Dr Wise on the Impact of Genetic Testing on Patient Outcomes in Prostate Cancer

January 15th 2024

David R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr D'Abreo on the Evolution of ADC Use in the HER2+ Breast Cancer Treatment Landscape

January 15th 2024

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.

Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCC

January 15th 2024

Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Dr Choi on the Potential Role For BTK Degraders in Relapsed/Refractory CLL

January 15th 2024

Michael Choi, MD, discusses key differences between BTK degraders & BTK inhibitors in the management of relapsed/refractory chronic lymphocytic leukemia.

Dr Ailawadhi on Non-BCMA CAR T-Cell Therapies Under Investigation in Multiple Myeloma

January 15th 2024

Sikander Ailawadhi, MD, discusses non-BCMA CAR T-cell therapies currently under investigation in multiple myeloma.

Dr Ailawadhi on the Potential Sequencing of Bispecific Antibodies in Multiple Myeloma

January 12th 2024

Sikander Ailawadhi, MD, shares considerations for the potential sequencing of bispecific antibodies and other BCMA-directed therapies in multiple myeloma.

Dr Kim on Selecting Between Frontline Immunotherapy-Based Regimens in HCC

January 12th 2024

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL

January 12th 2024

Tycel Phillips, MD, discusses the rationale for the phase 3 GLOBRYTE trial examining glofitamab in patients with relapsed/refractory mantle cell lymphoma.